Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients
First author：Yuesong Pan,Qidong Chen
Corresponding author：Yongjun Wang,Yilong Wang
essential_information
- Person in charge：Yuesong Pan,Qidong Chen
- Data Sources： TIMS-CHINA
- Number of papers：TIMS-CHINA20150130
- Published time：2014-05-26
2014-05-26
Published articles
Journal：Neurological Research
Publication type: Original Contributions
IF(IF): 2.448
PMID: 24861494 Link To Pubmed Full text Download
Background And Purpose
Previous studies have shown conflicting results on the use of antiplatelet (AP) agent and its risk of symptomatic intracerebral hemorrhage (sICH) following thrombolysis for acute ischemic stroke. Our study was to explore the safety of intravenous (IV) thrombolysis in Chinese stroke patients who were on AP prior to stroke.
Method
Data were collected from the thrombolysis implementation and monitor of acute ischemic stroke in China (TIMS-China) registry. Symptomatic ICH defined per SITS-MOST (safe implementation of treatments in stroke-monitoring study), ECASS II (second European-Australasian acute stroke study), and NINDS (National Institute of Neurological Disorders and Stroke) criteria, 90-day functional outcome, and 7- day and 90-day mortalities were compared between the stroke patients who were on mono and dual AP therapy.
Conclusion
The risk of developing sICH is low when thrombolysis is given to patients who are on ASA alone. However, there is potential increased risk of sICH if a patient is on dual AP treatment.
Main results
A total of 157 (14.2%) patients received at least one AP drug within 24 hours before thrombolysis. Patients with preexisting dual AP treatment had higher rate of sICH (14.3% (2/14) per SITS-MOST, 21.4% (3/14) per ECASS II definitions) than those on no AP treatment. No significant difference was found in the rate of sICH or 7-day or 90-day mortalities between the groups on aspirin (ASA) alone and on no AP treatment.